Lantheus recently released its latest 10-Q, and the filing describes a company that develops, manufactures and commercializes diagnostic and therapeutic products used in cardiac, cancer, pulmonary, neurologic and other disease settings. Its portfolio includes products such as DEFINITY, TechneLite, Xenon-133, Neurolite, Cardiolite and PYLARIFY, along with newer assets in radiodiagnostics, radiotherapeutics and software tools. The company is based in Bedford, Massachusetts, and says it sells primarily in the United States, with additional distribution and licensing activity abroad.
In Item 2, Management’s Discussion and Analysis, Lantheus said it now classifies revenue into four categories — Oncology, Neurology, Cardiology, and Strategic Partnerships and Other Revenue — after selling its SPECT business on Jan. 1, 2026. The company said the sale to SHINE SPECT closed on that date and that it received cash, notes receivable, a right to additional cash on the earlier of Jan. 1, 2030 or certain events, and contingent consideration.
Lantheus also said the Board approved a strategic program on Feb. 19, 2026 to simplify and streamline operations and focus mainly on radiodiagnostics while pursuing value-maximizing alternatives for radiotherapeutic assets. The company recorded $7.8 million of charges under that program in the three months ended March 31, 2026 and said it expects additional costs for the remainder of 2026.
Among recent developments, Lantheus said the FDA extended review of LNTH-2501’s NDA, moving the PDUFA date from March 29, 2026 to June 29, 2026 after the company submitted additional manufacturing-related information. It also said the FDA approved PYLARIFY TruVu on March 6, 2026, with commercial availability expected to begin in the fourth quarter of 2026 on a rolling geographic basis.
The company said PYLARIFY TruVu is intended to improve stability at higher radioactive concentrations, support larger batch sizes and expand manufacturing reach. Lantheus said it plans to seek reimbursement, including three years of transitional pass-through payment status.
On March 2, 2026, Lantheus said the FDA issued tentative approval for its ANDA for PNT2003, a radioequivalent version of LUTATHERA. The company said launch timing will depend on final FDA approval, the 30-month Hatch-Waxman stay and related legal proceedings, as well as manufacturing and commercial strategy.
Lantheus also highlighted the sale of its SPECT business as part of a broader portfolio shift and said it has been taking “purposeful, disciplined actions” over the past year to strengthen its commercial and development capabilities. The market has reacted to these announcements by moving the company's shares 2.42% to a price of $88.235. Check out the company's full 10-Q submission here.
